Search

Metyrosine

It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

Polysorbate 20

Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications. … It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions.

Albinterferon Alfa-2B

The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

Calcium phosphate dihydrate

Alemtuzumab

Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.[L43397] Alemtuzumab was approved by the FDA in 2001. … [L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

Avapritinib

Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]

Riluzole

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. … Riluzole is marketed as Rilutek by Sanofi.

Gimeracil

The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

Metaxalone

Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. … Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions.

Enmetazobactam

[A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious